Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

48 US States Support Mallinckrodt Opioid Settlement

However, Nassau County Opposed The Motion

Executive Summary

Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.

You may also be interested in...



Mallinckrodt’s Generics Business Will File For Bankruptcy

Last year, Mallinckrodt attempted restructuring the firm to evade bankruptcy fears. However, the company is now filing for bankruptcy for its US generics business to address “unmanageable liabilities.”

Alvotech And DKSH Partner On Adalimumab In Asia

Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.

India’s IPA Sees No Imminent Coronavirus Shortages

The Indian Pharmaceutical Alliance is working closely with the World Health Organization and International Generic and Biosimilar Medicines Association, as well as regional off-patent industry bodies in the US and Europe, to “navigate challenges on the manufacturing and logistics front” due to the coronavirus pandemic. Meanwhile, the IPA has welcomed domestic initiatives to boost API manufacturing.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel